If you have diabetes — Type 1, Type 2, or gestational — and haven’t had a dilated eye exam in the past year, stop reading this article and schedule one first. Under Medicare Part B, the annual dilated eye exam for diabetics is covered at 100% with no copay for most beneficiaries. Under most private insurance plans, it’s covered as a medical benefit. The exam that can prevent blindness may cost you nothing. The blindness it prevents would be permanent.
The Gap Between Preventable and Prevented
The CDC reports that 34.2 million Americans have diabetes — roughly 1 in 10. The National Eye Institute estimates that diabetic retinopathy affects 7.7 million Americans today, with projections reaching 14.6 million by 2050.
Here’s the part that should stop you: diabetic retinopathy is the leading cause of new blindness in working-age Americans. And the landmark NEI-funded Diabetic Retinopathy Study found that appropriate treatment reduces the risk of severe vision loss by 90–95%.
That gap between “leading cause of blindness” and “95% preventable” exists almost entirely because people with diabetes aren’t getting their annual dilated eye exams. A 2018 study in JAMA Ophthalmology found fewer than 50% of people with diabetes receive recommended annual retinal screenings. We have the tools to prevent most of this blindness. Most people at risk aren’t using them.
What Diabetic Retinopathy Actually Is
High blood sugar — chronically elevated over years — damages small blood vessels throughout the body. In the retina, those vessels are irreplaceable.
The damage progresses in stages:
Mild Nonproliferative Diabetic Retinopathy (NPDR) — microaneurysms form: tiny balloon-like swellings in retinal blood vessels that may leak small amounts of fluid. No symptoms. Vision is normal.
Moderate NPDR — more vessels are blocked. Some blood supply to the retina is cut off. Still no symptoms in most patients.
Severe NPDR — large areas of the retina are deprived of blood supply. The retina sends a chemical distress signal essentially requesting new vessel growth.
Proliferative Diabetic Retinopathy (PDR) — the body responds by growing new blood vessels on the retinal surface and into the vitreous gel. These new vessels are fragile and abnormal. They bleed easily, causing sudden vision loss. They can also cause tractional retinal detachment — scar tissue pulling the retina away from the back of the eye. This stage carries high risk of severe, permanent vision loss.
The most devastating feature of this progression: most patients have no symptoms until PDR or late-stage NPDR. No pain. Vision stays near-normal until disease is advanced. By the time you notice something is wrong, you may have already lost vision that can’t be recovered.
The Other Major Complication: Diabetic Macular Edema
Diabetic macular edema (DME) is the most common cause of vision loss in people with diabetic retinopathy. The macula — the central retinal area responsible for sharp detail vision — swells as fluid leaks from damaged vessels.
DME can occur at any retinopathy stage, including early stages. It causes blurring and distortion of central vision: the vision you use for reading, driving, and recognizing faces. Unlike peripheral vision loss (which you might not notice for years), DME can cause noticeable changes. But you still shouldn’t wait for symptoms — DME treated early responds much better.
Why Only a Dilated Exam Can Find This
This is the most important practical point: you cannot assess the retina without dilation.
In a standard vision check, the pupil is small. The view your doctor gets through an ophthalmoscope is narrow — not enough to reliably detect early retinopathy. Dilation drops widen the pupil to 6–8mm, allowing a full view of the retinal vascular tree from the optic nerve to the far periphery.
The exam itself takes 10–15 minutes once dilated. The drops take 20–30 minutes to work. Your near vision will be blurry and you’ll be light-sensitive for 4–6 hours afterward — bring sunglasses, and don’t plan to drive yourself home.
Many practices also use optical coherence tomography (OCT) — cross-sectional retinal imaging that allows precise measurement of retinal thickness and earlier detection of macular edema. This is standard of care at most ophthalmology practices and adds meaningful diagnostic value.
Treatment Costs When Disease Is Found
The cost difference between catching diabetic retinopathy early versus late is dramatic.
Mild to moderate NPDR: Better blood sugar control and blood pressure management may be the primary intervention. Monitoring visits every 6–12 months. Cost: $150–$300 per visit.
DME present: Anti-VEGF injections — ranibizumab (Lucentis), aflibercept (Eylea), bevacizumab (Avastin) — are the current gold standard. These drugs block the chemical signal driving abnormal vessel growth and fluid leakage. They’re injected into the vitreous in a brief in-office procedure, generally well-tolerated with topical anesthesia.
Proliferative DR: Laser photocoagulation (pan-retinal photocoagulation, or PRP) creates small burns across the peripheral retina, eliminating the oxygen-starved tissue that drives abnormal vessel growth. Anti-VEGF injections are also used at this stage.
Severe or late-stage disease: Vitrectomy surgery removes the vitreous gel and may be necessary for vitreous hemorrhage or tractional retinal detachment.
| Treatment | Typical Cost |
|---|---|
| Annual dilated eye exam (self-pay) | $150–$300 |
| Annual dilated exam under Medicare Part B | $0 (100% covered) |
| OCT retinal imaging | $75–$200 (often bundled with exam) |
| Anti-VEGF injection (Avastin/bevacizumab) | $50–$100/injection |
| Anti-VEGF injection (Lucentis/ranibizumab) | $1,800–$2,200/injection |
| Anti-VEGF injection (Eylea/aflibercept) | $1,900–$2,200/injection |
| Laser photocoagulation (PRP) | $1,500–$2,500 per eye per session |
| Vitrectomy surgery | $5,000–$10,000 per eye |
The cost spread between Avastin and the brand-name anti-VEGF drugs is striking. Bevacizumab (Avastin) was originally a cancer drug that ophthalmologists began using off-label for retinal disease; the NEI-funded CATT trial and multiple subsequent studies found it clinically equivalent to Lucentis at a fraction of the cost. Most retina specialists offer bevacizumab as the default option unless there’s a specific clinical reason to prefer otherwise. If cost is a concern, ask explicitly about bevacizumab.
Insurance Coverage for Diabetic Eye Care
Diabetic eye care is billed as a medical benefit, not a vision benefit — an important distinction.
Medicare Part B covers one dilated eye exam per year for beneficiaries with diabetes at 100% with no copay, when seen by an in-network ophthalmologist or optometrist. This is not the same as routine vision coverage — it’s diabetes preventive care.
Private insurance generally covers diabetic retinopathy exams, OCT imaging, and all treatments under medical benefits. Confirm your retina specialist or ophthalmologist participates in your plan. Anti-VEGF injections are typically covered with prior authorization.
Medicaid covers dilated eye exams and treatment in all states, with varying details by state.
The American Diabetes Association Standards of Medical Care recommends: Type 1 diabetics should have a dilated eye exam within 5 years of diagnosis and then annually. Type 2 diabetics should have one at diagnosis and then annually. If you’ve had multiple consecutive normal exams with well-controlled blood sugar, your ophthalmologist may extend the interval to every 2 years — but annually is the standard, and under Medicare it costs you nothing.
The Math on Early Detection
The Diabetic Retinopathy Study and Early Treatment Diabetic Retinopathy Study (ETDRS) established decades ago that timely treatment reduces the risk of severe vision loss by 90–95%. That’s not a modest improvement — it’s the difference between blindness and functional vision.
Annual dilated exams cost $150–$300 self-pay, zero under Medicare. Treating advanced proliferative diabetic retinopathy or vitreous hemorrhage runs $5,000–$10,000 per eye for surgery, plus months of anti-VEGF injections before and after. And unlike cataracts — where surgery fully restores vision — the vision loss from advanced diabetic retinopathy is often permanent.
The exam that prevents that outcome costs nothing under Medicare. For everyone else with diabetes, it’s the most cost-effective spending decision in eye care. Nothing else comes close.